MustGrow Announces Participation at Biocontrol Industry Conference and Investor Webinar
October 19, 2023 7:00 AM EDT | Source: MustGrow Biologics Corp.
Saskatoon, Saskatchewan--(Newsfile Corp. - October 19, 2023) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") will be participating in next week's Annual Biocontrol Industry Meeting ("ABIM") in Basel, Switzerland from October 23rd to 25th. ABIM is regarded as the premier event in the biocontrol industry. From policy makers, to farmers, to the end product users, global agriculture professionals attend ABIM each year to drive the sustainable agriculture industry forward.
For more information, please visit ABIM's website here.
"As a meeting place for the biocontrol industry, ABIM is internationally recognized and remains one of the best places to discover new products, to discuss market opportunities with multiple organizations, to present new research and products, and to liaise with fellow professionals. The large number of delegates attending the event demonstrates the continued importance of sustainable agriculture and MustGrow is excited to be a participant," Corey Giasson, MustGrow's President & CEO explains. "Biocontrols are essential in the transition of agriculture. These nature-based technologies can potentially improve biodiversity, soil quality, crop health and resilience contributing to sustainable food production."
MustGrow is also pleased to invite investors and the broader financial community to a fully interactive webinar hosted by President & CEO Corey Giasson and Chief Operating Officer Colin Bletsky. The webinar will take place on Tuesday, October 31st at 2:00 pm EDT and will consist of a 20-minute management presentation followed by an interactive question and answer session.
Please register in advance here.
After registering, you will receive a confirmation email containing information about joining the webinar. Prior to October 31st, please email questions to info@mustgrow.ca to be addressed during the Q&A portion of the webcast.
---------
About MustGrow
MustGrow is an agriculture biotech company developing organic biocontrol, soil amendment and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. MustGrow and its leading global partners -- Janssen PMP (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation, and Univar Solutions' NexusBioAg -- are developing mustard-based organic solutions to potentially replace harmful synthetic chemicals. Concurrently, with new formulations derived from food-grade mustard, the Company is pursuing the adoption and use of its technology in the soil amendment and biofertility markets. Over 150 independent tests have been completed, validating MustGrow's safe and effective approach to crop and food protection and yield enhancements. Pending regulatory approval, MustGrow's patented liquid products could be applied through injection, standard drip or spray equipment, improving functionality and performance features. Now a platform technology, MustGrow and its global partners are pursuing applications in several different industries from preplant soil treatment and weed control, to postharvest disease control and food preservation, to soil amendment and biofertility. MustGrow has approximately 50.1 million basic common shares issued and outstanding and 56.3 million shares fully diluted. For further details, please visit www.mustgrow.ca.
Contact Information
Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca
MustGrow Forward-Looking Statements
Certain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding its participation at the Annual Biocontrol Industry Meeting and the upcoming interactive webinar hosted by President & CEO Corey Giasson and Chief Operating Officer Colin Bletsky.
Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2022 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.
Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
© 2023 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/184483